Cargando…
Cardiotoxicity from immune checkpoint inhibitors
Immune checkpoint inhibitor (ICI) therapy has greatly improved treatment of various advanced cancers but increasing use of ICI therapy has exposed the risk of ICI-related cardiovascular side effects. Immune checkpoints are inhibitory regulators of T cell activation and mediate T cell effector functi...
Autores principales: | Michel, Lars, Rassaf, Tienush, Totzeck, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736791/ https://www.ncbi.nlm.nih.gov/pubmed/31517036 http://dx.doi.org/10.1016/j.ijcha.2019.100420 |
Ejemplares similares
-
Cardiac dysfunction from cancer and cancer therapy: new pathways for the prevention of late cardiotoxicity
por: Michel, Lars, et al.
Publicado: (2021) -
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
por: Totzeck, Matthias, et al.
Publicado: (2022) -
Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer—a meta‐analysis
por: Michel, Lars, et al.
Publicado: (2020) -
Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy
por: Pohl, Julia, et al.
Publicado: (2022) -
Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)